TAPUR
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 3,641 patients (estimated)
- Sponsors
- American Society of Clinical Oncology
- Collaborators
- Eli Lilly and Company, Bristol Myers Squibb, Genentech, Pfizer, Boehringer Ingelheim, Seattle Genetics, Taiho Oncology, Inc.
- Tags
- ROS1 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 801
- NCT Identifier
- NCT02693535
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.